ribociclib
novartis
['ribociclib']
maintain beautifully designed and presented by looked at the question of continuing cdk 4/6i beyond progression showed et + ribociclib improved pfs compared to et, 2.7 vs 5.2 mo, majority with fulvestrant as et #asco22 
Chief, Division of Breast Oncology @DanaFarber
Tennis fan
Mother of two teenage girls